Karo Bio's selective thyromimetics

Thyroid hormone receptors regulate both body weight and cholesterol levels, but nonselective stimulation of TRs can have deleterious effects, particularly in the heart. As a result, nonselective TR agonists, including endogenous thyroid hormone, are not useful metabolic therapies.

Last week, researchers at Karo Bio AB and Bristol-Myers Squibb Co. reported that they have developed an agonist that specifically targets the thyroid receptor beta subtype. The selective thyromimetic, KB-141, may be useful to treat obesity and/or lower cholesterol and lipoproteins without adverse cardiovascular effects...